Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRK Merck & Co., Inc.	$86.61 -0.6%	$91.57	$81.04 ▼ $134.63	$218.78B	0.4	11.12 million shs	10.58 million shs
MRNA Moderna	$27.72 +2.1%	$34.43	$26.32 ▼ $170.47	$10.72B	1.86	6.94 million shs	11.79 million shs
PCVX Vaxcyte	$33.69 +4.5%	$78.00	$30.12 ▼ $121.06	$4.34B	1.02	1.08 million shs	5.14 million shs
PFE Pfizer	$24.73 +0.8%	$26.00	$24.33 ▼ $31.54	$140.26B	0.61	39.24 million shs	41.78 million shs
STRO Sutro Biopharma	$0.63 +5.9%	$1.45	$0.58 ▼ $5.70	$51.98M	1.22	953,111 shs	1.11 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRK Merck & Co., Inc.	-2.97%	-0.92%	-5.59%	-12.47%	-33.49%
MRNA Moderna	-4.20%	-19.76%	-12.27%	-34.68%	-74.28%
PCVX Vaxcyte	-14.65%	-55.17%	-55.86%	-60.63%	-51.70%
PFE Pfizer	-3.27%	-4.05%	-7.21%	-7.56%	-11.46%
STRO Sutro Biopharma	-8.50%	-20.63%	-62.56%	-67.65%	-88.82%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	3.2	3.3	3.8
MRNA Moderna	4.353 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	1.3
PCVX Vaxcyte	1.9966 of 5 stars	3.5	0.0	0.0	0.0	3.8	2.5	0.0
PFE Pfizer	4.9858 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
STRO Sutro Biopharma	3.9683 of 5 stars	4.1	2.0	0.0	4.7	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	35.22% Upside
MRNA Moderna	2.04	Hold	$59.00	112.84% Upside
PCVX Vaxcyte	3.00	Buy	$136.50	305.16% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside
STRO Sutro Biopharma	2.22	Hold	$6.63	950.92% Upside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, MRNA, STRO, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2025	PCVX Vaxcyte	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$138.00 ➝ $100.00
4/1/2025	PCVX Vaxcyte	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$157.00 ➝ $137.00
4/1/2025	PCVX Vaxcyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$140.00 ➝ $90.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$12.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/14/2025	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/14/2025	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$8.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Underperform	$11.00 ➝ $1.00

(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRK Merck & Co., Inc.	$64.17B	3.41	$3.01 per share	28.82	$14.85 per share	5.83
MRNA Moderna	$3.20B	3.35	N/A	N/A	$28.33 per share	0.98
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$13.04 per share	N/A
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56
STRO Sutro Biopharma	$62.04M	0.84	N/A	N/A	$2.45 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRK Merck & Co., Inc.	$17.12B	$6.73	12.87	8.75	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PCVX Vaxcyte	-$402.27M	-$3.80	N/A	N/A	N/A	N/A	-23.53%	-22.20%	5/6/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
STRO Sutro Biopharma	-$106.79M	-$3.02	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	5/12/2025 (Estimated)

Latest PCVX, PFE, MRNA, STRO, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
3/13/2025	Full Year	STRO Sutro Biopharma	-$0.86	-$2.96	-$2.10	-$0.89	$10.44 million	$14.00 million
2/25/2025	Q4 2024	PCVX Vaxcyte	-$1.16	-$1.02	+$0.14	-$1.02	N/A	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRK Merck & Co., Inc.	$3.24	3.74%	+5.73%	48.14%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Latest PCVX, PFE, MRNA, STRO, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRK Merck & Co., Inc.	0.79	1.36	1.15
MRNA Moderna	N/A	3.67	3.62
PCVX Vaxcyte	N/A	17.88	17.88
PFE Pfizer	0.63	1.00	0.73
STRO Sutro Biopharma	N/A	3.09	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
PCVX Vaxcyte	96.78%
PFE Pfizer	68.36%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
MRK Merck & Co., Inc.	0.09%
MRNA Moderna	11.00%
PCVX Vaxcyte	3.10%
PFE Pfizer	0.06%
STRO Sutro Biopharma	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PCVX Vaxcyte	160	128.76 million	120.77 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
STRO Sutro Biopharma	240	82.46 million	77.59 million	Optionable

PCVX, PFE, MRNA, STRO, and MRK Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Hold" by Brokerages

April 2 at 2:55 AM | americanbankingnews.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1 at 5:11 AM | aaii.com

HC Wainwright Lifts Earnings Estimates for Sutro Biopharma

March 20, 2025 | marketbeat.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.com

Sutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC Wainwright

March 18, 2025 | marketbeat.com

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday

March 17, 2025 | marketbeat.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 17, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%

March 15, 2025 | aaii.com

Wedbush Downgrades Sutro Biopharma (STRO)

March 15, 2025 | msn.com

Sutro Biopharma (NASDAQ:STRO) Downgraded to Market Perform Rating by Citizens Jmp

March 15, 2025 | marketbeat.com

Wedbush Downgrades Sutro Biopharma (NASDAQ:STRO) to Neutral

March 15, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Lowered to "Underperform" Rating by Bank of America

March 15, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Announces Earnings Results

March 14, 2025 | marketbeat.com

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

March 14, 2025 | markets.businessinsider.com

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review

March 14, 2025 | biospace.com

New ADC focus as Sutro slashes workforce, drops lead drug

March 14, 2025 | thepharmaletter.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
By Jeffrey Neal Johnson | March 10, 2025
View Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality
Is Advanced Micro Devices Stock Slide Over?
By Thomas Hughes | March 5, 2025
View Is Advanced Micro Devices Stock Slide Over?
3 Stocks Near 52-Week Lows With Strong Rebound Potential
By Gabriel Osorio-Mazilli | March 31, 2025
View 3 Stocks Near 52-Week Lows With Strong Rebound Potential
5 ETFs Poised to Spring Ahead in the Second Quarter
By Chris Markoch | March 11, 2025
View 5 ETFs Poised to Spring Ahead in the Second Quarter
5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April

PCVX, PFE, MRNA, STRO, and MRK Company Descriptions

Merck & Co., Inc. NYSE:MRK

$86.61 -0.51 (-0.59%)

Closing price 03:58 PM Eastern

Extended Trading

$86.22 -0.39 (-0.44%)

As of 08:00 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$27.72 +0.56 (+2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$26.50 -1.22 (-4.38%)

As of 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Vaxcyte NASDAQ:PCVX

$33.69 +1.46 (+4.53%)

Closing price 04:00 PM Eastern

Extended Trading

$31.84 -1.85 (-5.49%)

As of 07:55 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 03:59 PM Eastern

Extended Trading

$24.47 -0.26 (-1.05%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sutro Biopharma NASDAQ:STRO

$0.63 +0.04 (+5.90%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 -0.02 (-2.44%)

As of 06:21 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PCVX, PFE, MRNA, STRO, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PCVX, PFE, MRNA, STRO, and MRK Earnings

Compare Dividends

Latest PCVX, PFE, MRNA, STRO, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PCVX, PFE, MRNA, STRO, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PCVX, PFE, MRNA, STRO, and MRK Company Descriptions

Merck & Co., Inc. NYSE:MRK

Moderna NASDAQ:MRNA

Vaxcyte NASDAQ:PCVX

Pfizer NYSE:PFE

Sutro Biopharma NASDAQ:STRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools